ArticleJournal of virology2012
NS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge.
Article in Journal of virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 69 citations in OpenAlex.
- A CXCL10-Expressing Influenza Vector Induces Robust Adaptive Immunity Despite Strong Attenuation.Pharmaceutics · 2026Article
- Article
- Generation of an autophagy-targeting influenza A virus as live attenuated vaccine.Nature communications · 2026Article
- Novel Intranasal Replication-Deficient NS1ΔC Flu Vaccine Confers Protection from Divergent Influenza A and B Viruses in Mice.Vaccines · 2025Article
- Intranasal NS1-truncated live attenuated canine influenza vaccine confers superior protection compared to inactivated vaccine in beagles.Veterinary research · 2025Article
- Review
- Article
- Intranasal influenza virus-vectored vaccine offers protection against clade 2.3.4.4b H5N1 infection in small animal models.Nature communications · 2025Article
- The applications of live attenuated influenza a virus with modified NS1 gene.Molecular therapy. Nucleic acids · 2025Review
- Antiviral responses versus virus-induced cellular shutoff: a game of thrones between influenza A virus NS1 and SARS-CoV-2 Nsp1.Frontiers in cellular and infection microbiology · 2024Review
- An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters.Nature communications · 2023Article
- Article
- Reprogramming viral immune evasion for a rational design of next-generation vaccines for RNA viruses.Frontiers in immunology · 2023Review
- Silent neonatal influenza A virus infection primes systemic antimicrobial immunity.Frontiers in immunology · 2023Article
- Optimizing the Live Attenuated Influenza A Vaccine Backbone for High-Risk Patient Groups.Journal of virology · 2022Article
- Lignin: A Sustainable Antiviral Coating Material.ACS sustainable chemistry & engineering · 2022Article
- Development of a T Cell-Based COVID-19 Vaccine Using a Live Attenuated Influenza Vaccine Viral Vector.Vaccines · 2022Article
- Live attenuated influenza A virus vaccines with modified NS1 proteins for veterinary use.Frontiers in cellular and infection microbiology · 2022Review
- Equine Influenza Virus and Vaccines.Viruses · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Immunological changes associated with age contribute to the high rates of influenza virus morbidity and mortality in the elderly. Compounding this problem, aged individuals do not respond to vaccination as well as younger, healthy adults. Efforts to increase protection to this demographic group are of utmost importance, as the proportion of the population above the age of 65 is projected to increase in the coming decade. Using a live influenza virus with a truncated nonstructural protein 1 (NS1), we are able to stimulate cellular and humoral immune responses of aged mice comparable to levels seen in young mice. Impressively, a single vaccination provided protection following stringent lethal challenge in aged mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.